Medicare Price Negotiation Savings Would Rise To $101Bn With Revisions To Legislation – CBO
Executive Summary
Latest version of Medicare price negotiation and price inflation rebate provisions are expected to lower federal government costs by about $200bn over 10 years.
You may also be interested in...
Medicare Price Negotiation Will Disrupt Rebating In Part D; The Question Is How Much
Congressional Budget Office maps out how current rebating practices may change in Medicare Part D under the drug pricing provisions of the Inflation Reduction Act.
US Pricing Reform Puts Cancer Drug Innovation At Risk, Drug Leaders Warn
Merck & Co. CEO Rob Davis, Regeneron president George Yancopoulos, Pfizer R&D president Mikael Dolsten and others weighed in at the Galien Forum on the potential impact of the US Inflation Reduction Act on innovation.
‘A Forever Battle:’ Patent Reform, Launch Prices, And Where Lower Rx Price Advocates Will Go Next
Pharma’s opponents believe passage of the Inflation Reduction Act represents a momentum shift that will make it easier for politicians (even some Republicans) to take on the industry. They’ll need to count on that as they still have a long list of targets ahead on their lower-drug pricing agenda.